The impact of hydroxyurea on career and employment of patients with sickle cell anemia

Journal of the National Medical Association

Volumn 102, Issue 11, 2010, Pages 993-999

  Ballas, Samir K ^a   Bauserman, Robert L ^b   McCarthy, William F ^b   Waclawiw, Myron A ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Hydroxyurea; Sickle cell anemia

Indexed keywords

HYDROXYUREA; PLACEBO;

ADULT; ARTICLE; AVASCULAR NECROSIS; CAREER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EMPLOYMENT; FEMALE; HEALTH BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; TREATMENT RESPONSE;

EID: 78650116768     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30725-2     Document Type: Article

References (27)

1. Ballas SK, Park CH, Jacobs SR, The spectrum of painful episodes in adult sickle cell disease. Pain Digest. 1995;5:73-89.
2. Ballas SK. Treatment of pain in adults with sickle cell disease. Am J Hematol. 1990;34:49-54.
3. Evans GR. Haemoglobin disorders and their occupational implications. Occup Med. 1994;44:29-33.
4. Brandon W. Sickle cell disease and the adult patient. Minority Nurse Newsl. 1995;2:1.
5. Hull DH. Other important medical conditions. In: Ernsting J, King P, eds. Aviation Med. London, England: Butterworths; 1988;616.
6. Franklin IM, Atkin K. Employment of persons with sickle-cell disease and sickle-cell trait. J Soc Occup Med. 1986;36:76-79.
7. Archibald RMCL, Kemp HBS, Marks LH, et al. Orthopaedics. In: Edwards FC, McCullum RI, Taylor PH, eds. Fitness for Work: The Medical Aspects. Oxford, England: Oxford University Press; 1990;126-141.
8. Mann JR. Sickle cell haemoglobinopathies in England. Arch Dis Child. 1981;56:676.
9. Abrams MR, Phillips G Jr, Whifworth E. Adaptation and coping: a look at a sickle cell disease population over age 30 - an integral phase of life long development process. In: Nash KB, ed. Psychosocial Aspects Sickle Cell Dis. New York, NY: The Haworth Press; 1994:141-160.
10. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
11. Charache S, Terrin ML, Moore RD, et al. Design of the Multicenter Study of Hydroxyurea in sickle cell anemia. Controlled Clinical Trials. 1995;6:432-446. (Pubitemid 26035810)
12. Bunn, HF. Induction of fetal hemoglobin in sickle cell disease. Blood. 1999;93:1787-1789.
13. Valafar, H, Valafar, F, Darvill, A, et al. Predicting the effectiveness of hydroxyurea in individual sickle cell patients. J Artificial Intelligence Med. 2000;18:133-148.
14. National Heart Lung Blood Institute. The management of Sickle Cell Disease. NIH Publication 02-2117.2002.
15. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well being of patients with chronic conditions. JAMA. 1989;262:907-913.
16. Woods KF, Miller MD, Johnson MH, et al. Functional status and well being in adults with Sickle Cell Disease. JCOM. 1997;4:15-21. (Pubitemid 127123402)
17. Revicki DA. Health-related quality of life in the evaluation of medical therapy for chronic illness. J Fam Pract. 1989;29:377-380.
18. Ferrell BR, Wisdom C, Wenzl C. Quality of life as an outcome variable in the management of cancer pain. Cancer. 1989,63:2321-2327. (Pubitemid 19141079)
19. Hanestad BR, Albrektsen G. Qualify of life: perceived difficulties in adherence to a diabetes regimen, and blood glucose control. Diabef Med. 1991;8:759-764.
20. Harati Y, Gooch C, Swenson M, et al. Double blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neuropathy. 1998;50:1842-1846. (Pubitemid 28283262)
21. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. JAMA. 1998;280:1837-1842.
22. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the Symptomatic treatment of painful Neuropathy in patients with Diabetes Mellitus. JAMA. 1998;280:1831-1836. (Pubitemid 28544423)
23. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect of life. Health Qua/ Life Outcomes. 2006;4:59-66.
24. Farber MD, Koshy M, Kinney TR. The Cooperative study of sickle cell disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis. 1985;48:495-505.
25. Damjouli NF, Kevess-Cohen R, Chrache S, et al. Social disability and psychiatric morbidity in sickle cell anemia and diabetes patients. Psychosomatics. 1982;23:925-931.
26. Barrett DH, Wisotez IE, Rouleau JL, et al. Assessment of psychosocial functioning of patients with sickle cell disease. South Med J. 1988;81:745-750.
27. Steinberg MH, Barton F, Castro O, et al. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits up to 9 Years of Treatment. JAMA. 2003; 289:1645-1651.